NASDAQ · Biotechnology · USD

SpyGlass Pharma, Inc. (SGP) Stock Analysis

SpyGlass Pharma, Inc. (SGP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SGP

$28.94

−$0.05 (−0.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SGP with… →

SGP Key Statistics

As of Sep 4, 2026

Trading

Open: $28.81
Previous Close: $28.99
Day's Range: 28.03–29.18
52-Week Range: 17.06–32.44
Volume: 75.10K

Valuation

Market Cap: $967.98M
P/E Ratio: unprofitable
EPS (ttm): −1.68

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$39.87M
Profit margin: 0.00%
Shares Outstanding: 33.45M

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 118.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SGP Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$39.87M	—
2024	$0.00	−$29.16M	—
2023	$0.00	−$13.32M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$41.45M	−$39.87M	—
2024	$0.00	—	−$27.06M	−$29.16M	—
2023	$0.00	—	−$14.23M	−$13.32M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SGP Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SGP	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values SpyGlass Pharma, Inc. (SGP) at $967.98M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 76.

Over the past 52 weeks the price has ranged from $17.06 to $32.44. The most recent close on file for SGP is $28.94, dated September 4, 2026. That is −$0.05 (−0.17%) against the previous close. The latest close sits 69.64% above that 52-week low.

Financial Health

In fiscal 2025, SpyGlass Pharma, Inc. reported revenue of $0.00. The same year closed with a net loss of $39.87M. Profit margin runs at 0%. Trailing earnings per share are −1.68.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on February 6, 2026, and the total return since then is +9.62%.

Growth & Income

No dividend is on file for SGP.

So far in 2026 the price is +9.62%.

Peer Comparison

SpyGlass Pharma, Inc. (SGP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
SpyGlass Pharma, Inc.	SGP	$967.98M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. SpyGlass Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

Visit website →